• All studies should be conducted by a team of researchers with multidisciplinary knowledge and experience. The Zimbabwean institution to which the main researcher is affiliated must be responsible for the trial; 2. Guiding principal 2: Vaccine availability: Any HIV preventive or therapeutic vaccine demonstrated to be safe and effective should be made available as soon as possible to all participants of the trial in which it was tested as well as other at risk groups. • Parties directly concerned should begin the discussion before the trials begin. This discuss should include stakeholders such as Ministry of Health, Local Authorities, scientific and ethical groups, NGOs, PLWHA and community representatives. 3. Guiding Principal 3: Capacity building. Strategies should be implemented to build capacity in Zimbabwe and in communities to ensure meaningful self determination in vaccine development, ethical and scientific conduct of vaccine trials and allow Zimbabwe to function as an equal partner with sponsor countries in the collaborative process. • Develop capacity and capability to make decisions regarding nature and participation in vaccine trials as well as being able to identify factors that increase vulnerability to exploitation of communities • Study sponsors should ensure their full support to the institutions involved in the HIV vaccine trials to develop the research potential required by the trial, including training of personnel, logistic support and infrastructure;. 20